[1] LIAO S H, SU T H, JENG Y M, et al.Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma[J]. Hepatology, 2019, 69(1): 209-221.
[2] YAMAMOTO Y, OJIMA H, SHIMADA K, et al.Long-term recurrence-free survival in a patient with primary hepatic carcinosarcoma: case report with a literature review[J]. Jpn J Clin Oncol, 2010, 40(2): 166-173.
[3] LU J, ZHANG J, XIONG X Z, et al.Primary hepatic sarcomatoid carcinoma: clinical features and prognosis of 28 resected cases[J]. J Cancer Res Clin Oncol, 2014, 140(6): 1027-1035.
[4] MARIJON H, DOKMAK S, PARADIS V, et al.Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma[J]. J Hepatol, 2011, 54(5): 1073-1078.
[5] Wu Z, Wei Y, Cai Z, et al.Long-term survival outcomes of undifferentiated embryonal sarcoma of the liver:A pooled analysis of 308 patients[J]. ANZ J Surg, 2020, 90(9): 1615-1620.
[6] KAN A, GUO R P.The prognosis of subsequent surgical treatment in patients with sarcomatoid carcinoma in the liver: a retrospective study[J]. Int J Surg, 2018, 55: 145-151. |
